Point 27

Point27 is a biotechnology company dedicated to developing next-generation cytokine immunotherapies, with a primary focus on Interleukin-27 (IL-27). The company utilizes a proprietary protein engineering platform to design cytokines with improved therapeutic profiles, aiming to maximize anti-tumor activity while minimizing systemic toxicity. By modulating the IL-27 pathway, Point27 seeks to overcome immune suppression in the tumor microenvironment and enhance the efficacy of existing treatments. The company's research is based on foundational work from Yale University and is supported by leading life science investors. Currently in the pre-clinical stage, Point27 is advancing its lead programs toward clinical validation for various oncology indications.